Current status and future trends of the global burden of MASLD

Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 35(8), P. 697 - 707

Published: Feb. 29, 2024

Language: Английский

---

The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(2), P. 428 - 428

Published: Jan. 10, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern, and it not only the keystone precursor of eventual liver-related morbidity, but also places patients at considerably higher cardiovascular risk, which still a leading cause death in these patients. The most important common underlying pathophysiological mechanisms diseases are primarily related to insulin resistance, chronic inflammation oxidative stress. presence MASLD with (CVD) type 2 diabetes mellitus (T2DM) elevates risk for poor outcomes, thus this review highlights method therapeutic approaches. Given intertwined nature MASLD, T2DM, CVD, there urgent need strategies that address all three conditions. Although lifestyle changes as treatment, medication plays crucial role managing hyperglycemia, enhancing function lowering risk. onset progression should be addressed through multifaceted approach, targeting inflammatory, immune, metabolic, stress, hormonal gutaxis pathways, alongside treatment T2DM. In review, we discuss effects antidiabetic drugs impact on both outcomes affected by T2DM CDV.

Language: Английский

---

In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome

Diabetes Obesity and Metabolism, Journal Year: 2023, Volume and Issue: 25(11), P. 3093 - 3102

Published: Aug. 3, 2023

Abstract Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also improving beta cell function. Because of the improved function control that occurs with pioglitazone is prolonged. has positive effects on cardiac risk factors and surrogate measures cardiovascular disease, it lowers incidence events in patients diabetes. The recurrence transient ischaemic attack stroke reduced non‐diabetic, insulin‐resistant subjects. Utilized at preclinical stages (but later) heart failure, diastolic avoids progression to failure. Pioglitazone, through suppression atrial remodelling, decreases fibrillation. manifestations diseases associated resistance (non‐alcoholic steatohepatitis polycystic ovary disease) are pioglitazone. may possibly improve psoriasis other dermopathies. therefore an inexpensive efficacious drug for subject diabetes underutilized because biases have evolved from toxicities thiazolidinediones.

Language: Английский

---

Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 59(7), P. 802 - 811

Published: Jan. 31, 2024

Summary Background Fibroblast growth factor 21 (FGF21) analogues have emerged as promising therapeutic targets for non‐alcoholic steatohepatitis (NASH). However, the effects and safety of these on NASH NASH‐related fibrosis remain unexplored. Aims To estimate efficacy FGF21 treating fibrosis. Methods PubMed, Embase, Cochrane Library were searched relevant studies up to 11 October 2023. Primary outcomes defined improvement ≥1 stage without worsening resolution Secondary included biomarkers fibrosis, liver injury, metabolism. Treatment‐related adverse events also analysed. Results Nine studies, including 1054 patients with biopsy‐proven F1–F4 identified. Seven reported histological outcomes. The relative risk (RR) obtaining was 1.79 (95% CI 1.29–2.48, I 2 = 37%, p < 0.001) placebo. Although no statistically significant difference observed between in resolution, sensitivity analyses fragility index suggest that this result is unstable. drugs improved hepatic fat fraction (HFF), along other metabolism (MRE, LSM, Pro‐C3, ELF, ALT, AST, TG, HDL‐C, LDL‐C). Additionally, serious event incidence rate (RR 1.26, 95% 0.82–1.94, 24%, 0.3). Conclusions appear agents treatment they generally seem be safe well tolerated.

Language: Английский

---

Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Aug. 17, 2023

Non-alcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent worldwide, especially in people with obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and metabolic syndrome. Weight loss dietary modifications are established first-line treatments for NAFLD. Currently, there no approved drug NAFLD; however, pioglitazone vitamin E have shown some beneficial effects. This systematic review covers the comparative efficacies of E, pioglitazone, plus pioglitazone. As December 2022, sources prior literature included PubMed, PubMed Central, Medline. We studies assessing efficacy improving histology, markers, lipid profile when compared to other interventions patients NAFLD/non-alcoholic steatohepatitis (NASH). Review materials include randomized control trials (RCTs), traditional reviews, meta-analyses, observational on human participants published within last five years English language. Studies animals, pediatric populations, insufficient data were excluded from review. Two authors scanned filtered articles independently later performed quality checks. A third reviewer resolved any conflicts. The risk bias was assessed using Preferred Reporting Items Systematic Reviews Meta-Analyses 2020 guidelines Cochrane Risk Bias Tool RCTs, Scale Assessment Narrative Articles Traditional Reviews. total 21 shortlisted. results showed that effective reducing steatosis, inflammation, ballooning, but seem be conflicting fibrosis resolution. Pioglitazone decreases triglycerides increases high-density lipoproteins. One study has suggested superior reduction than alone NASH However, these conclusions require further validation through extensive analysis additional research. In conclusion, diabetic NAFLD can given non-diabetic E.

Language: Английский

---

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(7), P. 6300 - 6314

Published: June 21, 2024

With around one billion of the world's population affected, era metabolic-associated fatty liver disease (MAFLD) pandemic has entered global stage. MAFLD is a chronic progressive with accompanying metabolic disorders such as type 2 diabetes mellitus and obesity which can progress asymptomatically to cirrhosis subsequently hepatocellular carcinoma (HCC), for date there are almost no approved pharmacologic options. Because very complex etiology it also affects extrahepatic organs, multidisciplinary approach required when comes finding an effective safe active substance treatment. The optimal drug should diminish steatosis, fibrosis inflammation in liver, winner authorisation seems be that significantly improves histology. Saroglitazar (Lipaglyn

Language: Английский

---

Exploring the Mechanism of Action of GLP-1RAs in the Treatment of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Based on Network Pharmacology

Medical Diagnosis, Journal Year: 2025, Volume and Issue: 15(02), P. 200 - 210

Published: Jan. 1, 2025

Language: Английский

---

AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study

Liver International, Journal Year: 2024, Volume and Issue: 44(10), P. 2572 - 2582

Published: July 4, 2024

Lifestyle intervention is the mainstay of therapy for metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis a key consequence MASH that predicts adverse clinical outcomes. The placebo response plays pivotal role in outcome trials. Second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy with artificial intelligence analyses can provide an automated quantitative assessment features on continuous scale called qFibrosis. In this exploratory study, we used approach to gain insight into effect lifestyle intervention-induced changes MASH.

Language: Английский

---

Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury

Molecules, Journal Year: 2024, Volume and Issue: 29(15), P. 3537 - 3537

Published: July 27, 2024

Liver disease is a global health problem that affects the well-being of tens thousands people. Dihydroquercetin (DHQ) flavonoid compound derived from various plants. Furthermore, DHQ has shown excellent activity in prevention and treatment liver injury, such as inhibition hepatocellular carcinoma cell proliferation after administration, normalization oxidative indices (like SOD, GSH) this tissue, down-regulation pro-inflammatory molecules (such IL-6 TNF-α). also exerts its therapeutic effects by affecting molecular pathways NF-κB Nrf2. This paper discusses latest research progress diseases (including viral drug alcoholic non-alcoholic fatty immune injury). It explores how to optimize application improve effectiveness treating diseases, which valuable for preparing potential drugs human conjunction with DHQ.

Language: Английский

---

Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection

Cancers, Journal Year: 2023, Volume and Issue: 15(4), P. 1148 - 1148

Published: Feb. 10, 2023

Previous studies have indicated that HBV infection and T2DM are the factors increase risk of developing HCC. The experimental evidence has shown antiglycemic agents may reduce However, effect dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) on HCC in patients with chronic remains unclear. In this retrospective cohort study, we extracted from National Health Insurance Research Database (NHIRD) Taiwan. cases were divided into DPP-4 use non-use groups, according to whether they received treatment, was compared between two groups. At end follow-up, approximately 2.33% users had an diagnosis 3.33% non-DPP-4 (p < 0.0001). After multivariate adjustment, showed a significant reduction (adjusted hazard ratios (aHRs): 0.53; 95% confidence intervals (CIs): 0.44–0.65). conclusion, population-based study that, infection, significantly reduced use.

Language: Английский

---